CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 48 enrolled
Drug / intervention
Stereotactic Body Radiation Therapy (SBRT)radiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01781728
NCT01781728Phase 2Completed
CompareCT.gov

Phase II Study to Evaluate Stereotactic Body Radiation Therapy For Palliative Management of Unresectable Recurrent or Residual Pancreatic or Periampullary Adenocarcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Feb 1, 2013·Updated Jul 20, 2025

In Brief

A Phase 2 clinical trial evaluating Stereotactic Body Radiation Therapy (SBRT) for Pancreatic Cancer and Periampullary Adenocarcinoma. Completed, enrolled 48 participants across 1 site.

Detailed Summary

The investigators are looking to see if a certain dose of stereotactic body radiation therapy (SBRT) may be a viable treatment option for recurrent or residual pancreatic or periampullary adenocarcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer, Periampullary Adenocarcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 1, 2013
Enrollment StartJan 1, 2013
Primary CompletionMar 1, 2021
Study CompletionJun 1, 2024
TodayJul 2, 2026
Enrollment to primary: 8.2 yearsPosted 13.4 years ago

Interventions

Stereotactic Body Radiation Therapy (SBRT)radiation

Stereotactic Body Radiation Therapy (SBRT) which included 5 consecutive fractions of 25 to 33 Gy, following 3 months of multiagent chemotherapy.